DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Expedited Licensure Options for Evacuees from Puerto Rico
October 30, 2017

The Board of Dentistry has important updates for applicants from Puerto Rico who are seeking expedited licensure and work authorization in Florida. Continue reading


Urgent National Drug Shortage
October 16, 2017

Please Click for Details on the Urgent National Drug Shortage: Lidocaine with Epinephrine and Bupivacaine with Epinephrine Continue reading